|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5000 CAD | -.--% |
|
-1.96% | +9.89% |
| 06-03 | PharmaCorp Rx Initiated at Outperform, $0.70 Price Target at Raymond James | MT |
| 06-01 | Earnings Flash (PCRX.V) PharmaCorp Reports Q1 Revenue $7.2M, Up 79.4% YoY | MT |
Company Valuation: PharmaCorp Rx Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 63.34 | 75.95 | 87.04 | - | - |
| Change | - | 19.91% | 14.6% | - | - |
| Enterprise Value (EV) 1 | 63.34 | 53.55 | 95.64 | 89.94 | 101.3 |
| Change | - | -15.46% | 78.61% | -5.96% | 12.62% |
| P/E | -54x | -45.5x | - | - | - |
| PBR | - | - | 1.67x | 1.56x | - |
| PEG | - | - | - | - | - |
| Capitalization / Revenue | - | 3.64x | 1.8x | 0.9x | 1.01x |
| EV / Revenue | - | 2.56x | 1.97x | 0.93x | 1.18x |
| EV / EBITDA | - | 15.2x | 20.3x | 8.14x | 8.96x |
| EV / EBIT | - | - | 43.1x | 12.7x | 12.1x |
| EV / FCF | - | 27.9x | -41.1x | 15.2x | 14.3x |
| FCF Yield | - | 3.58% | -2.43% | 6.6% | 6.98% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -0.01 | -0.01 | - | - | - |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | - | 20.89 | 48.48 | 96.23 | 86.17 |
| EBITDA 1 | - | 3.528 | 4.707 | 11.06 | 11.31 |
| EBIT 1 | - | - | 2.217 | 7.074 | 8.385 |
| Net income | -1.013 | -1.481 | - | - | - |
| Net Debt 1 | - | -22.4 | 8.6 | 2.9 | 14.25 |
| Reference price 2 | 0.5400 | 0.4550 | 0.5000 | 0.5000 | 0.5000 |
| Nbr of stocks (in thousands) | 117,296 | 166,927 | 174,082 | - | - |
| Announcement Date | 22/04/25 | 29/04/26 | - | - | - |
1CAD in Million2CAD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | 1.97x | 20.32x | - | 61.29M | |
| 15.48x | 0.59x | 9.28x | -.--% | 13.38B | |
| 19.09x | 0.91x | 14.13x | -.--% | 6.35B | |
| 15.79x | 0.7x | 7.32x | 2.36% | 5.62B | |
| 15.67x | 0.95x | 7.1x | 4.12% | 3.31B | |
| 14.4x | 1.22x | 7.42x | 5.74% | 3.24B | |
| 11.34x | 0.71x | 5.1x | 3.79% | 3.4B | |
| 40.85x | - | - | - | 2.67B | |
| 11.53x | 0.45x | 3.62x | 5.99% | 2.71B | |
| Average | 18.02x | 0.94x | 9.29x | 3.14% | 4.52B | |
| Weighted average by Cap. | 17.07x | 0.75x | 8.69x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PCRX Stock
- Valuation PharmaCorp Rx Inc.
Select your edition
All financial news and data tailored to specific country editions
